In Development for Cystic FibrosisPhase 1NCT01153542
Study of VX-770 on Desipramine
A Phase 1 study testing VX-770 in people with In Development for Cystic Fibrosis, run by Vertex Pharmaceuticals Incorporated at 1 site in United States.
Trial summary
The objective of this study is to evaluate the effects of VX-770 on Desipramine Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- In Development for Cystic Fibrosis
- What is being tested?
- VX-770
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2010to Aug 2010
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Subjects must be male or female and between 18 and 55 years of age
- Subject must have a body mass index (BMI) from 18 to 30 kg/m2
- Subject must be judged to be in good health
Who cannot join
- History of any illness that, in the opinion of the investigator or the subject's general practitioner, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject
- Subjects who have human immunodeficiency virus, hepatitis C, or active hepatitis B
- Female subjects and male subjects with female partner(s) who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of the last dose of study drug
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open-Label Phase 1 Study to Examine the Effect of VX 770 on Desipramine in Healthy Subjects
The objective of this study is to evaluate the effects of VX-770 on Desipramine
- Conditions
- In Development for Cystic Fibrosis
- Being tested
- VX-770
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VX-770Drug
In period 1, subjects will receive a single oral dose of desipramine on Day 1.
VX-770Drug
In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.
| Study group | Role | What they receive |
|---|---|---|
| VX-770 | Experimental | Not described Receives: Drug: VX-770 |
| desipramine | Experimental | Not described Receives: Drug: VX-770 |
What is being measured
The primary outcome is the main question the study is designed to answer.
VX-770 and Desipramine pharmacokinetic parameters
Measured: 3 weeks
Secondary outcomes (2)
Safety as measured by adverse events, vital signs, electrocardiograms (ECGs), and clinically significant laboratory assessments
Measured: 3 weeks
Metabolites pharmacokinetic parameters in plasma
Measured: 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2010 (estimated)
- Study startJun 2010
- Primary completionAug 2010
- Study completionAug 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for In Development for Cystic FibrosisStudies of the same condition, open and under way.
- More trials run by Vertex Pharmaceuticals IncorporatedThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- H. Frank Farmer, MD, Principal investigator, Covance CRU, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01153542
- Sponsor's protocol ID
- VX10-770-011
- Status last verified
- Dec 2010
- First submitted
- 28 Jun 2010
- Last updated
- 9 Dec 2010
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Dec 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label Phase 1 Study to Examine the Effect of VX 770 on Desipramine in Healthy Subjects
- ClinicalTrials.gov ID
- NCT01153542
- Acronym / sponsor ID
- VX10-770-011
- Conditions
- In Development for Cystic Fibrosis
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedIndustry (pharma, biotech, devices)
- Study start
- Jun 2010
- Primary completion
- Aug 2010 (actual)
- Study completion
- Aug 2010 (actual)
- First posted
- 30 Jun 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to evaluate the effects of VX-770 on Desipramine
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| VX-770 | Experimental | Drug: VX-770 |
| desipramine | Experimental | Drug: VX-770 |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Subjects must be male or female and between 18 and 55 years of age
- Subject must have a body mass index (BMI) from 18 to 30 kg/m2
- Subject must be judged to be in good health
Key exclusion criteria (3 listed)
- History of any illness that, in the opinion of the investigator or the subject's general practitioner, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject
- Subjects who have human immunodeficiency virus, hepatitis C, or active hepatitis B
- Female subjects and male subjects with female partner(s) who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of the last dose of study drug
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VX-770In period 1, subjects will receive a single oral dose of desipramine on Day 1. | Drug | desipramine |
| VX-770In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2. | Drug | VX-770, desipramine |
Primary outcome
VX-770 and Desipramine pharmacokinetic parameters
Time frame: 3 weeks
2 secondary outcomes
Safety as measured by adverse events, vital signs, electrocardiograms (ECGs), and clinically significant laboratory assessments
Time frame: 3 weeks
Metabolites pharmacokinetic parameters in plasma
Time frame: 3 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Dec 2010.
Related trials for In Development for Cystic Fibrosis
RecruitingObservational study
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease
RecruitingObservational study
Bronchiectasis Phenotype Identification Model
Bronchiectasis, Non-cystic Fibrosis Bronchiectasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
H. Frank Farmer, MD principal investigator
Covance CRU, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing VX-770 in people with In Development for Cystic Fibrosis, run by Vertex Pharmaceuticals Incorporated at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Dec 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
VX-770 and Desipramine pharmacokinetic parameters (time frame: 3 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2010.